Acetohydroxamic acids as potent, selective, orally active 5-lipoxygenase inhibitors. 1988

W P Jackson, and P J Islip, and G Kneen, and A Pugh, and P J Wates
Wellcome Research Laboratories, Beckenham, Kent, United Kingdom.

UI MeSH Term Description Entries
D007962 Leukocytes White blood cells. These include granular leukocytes (BASOPHILS; EOSINOPHILS; and NEUTROPHILS) as well as non-granular leukocytes (LYMPHOCYTES and MONOCYTES). Blood Cells, White,Blood Corpuscles, White,White Blood Cells,White Blood Corpuscles,Blood Cell, White,Blood Corpuscle, White,Corpuscle, White Blood,Corpuscles, White Blood,Leukocyte,White Blood Cell,White Blood Corpuscle
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006877 Hydroxamic Acids A class of weak acids with the general formula R-CONHOH. Hydroxamic Acid,Acid, Hydroxamic,Acids, Hydroxamic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001091 Arachidonate Lipoxygenases Enzymes catalyzing the oxidation of arachidonic acid to hydroperoxyarachidonates. These products are then rapidly converted by a peroxidase to hydroxyeicosatetraenoic acids. The positional specificity of the enzyme reaction varies from tissue to tissue. The final lipoxygenase pathway leads to the leukotrienes. EC 1.13.11.- . Arachidonic Acid Lipoxygenase,Lipoxygenase, Arachidonic Acid,Lipoxygenases, Arachidonate
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D016859 Lipoxygenase Inhibitors Compounds that bind to and inhibit that enzymatic activity of LIPOXYGENASES. Included under this category are inhibitors that are specific for lipoxygenase subtypes and act to reduce the production of LEUKOTRIENES. 5-Lipoxygenase Inhibitor,Lipoxygenase Inhibitor,12-Lipoxygenase Inhibitors,15-Lipoxygenase Inhibitors,5-Lipoxygenase Inhibitors,Arachidonate 12-Lipoxygenase Inhibitors,Arachidonate 15-Lipoxygenase Inhibitors,Arachidonate 5-Lipoxygenase Inhibitors,Inhibitors, Lipoxygenase,12 Lipoxygenase Inhibitors,12-Lipoxygenase Inhibitors, Arachidonate,15 Lipoxygenase Inhibitors,15-Lipoxygenase Inhibitors, Arachidonate,5 Lipoxygenase Inhibitor,5 Lipoxygenase Inhibitors,5-Lipoxygenase Inhibitors, Arachidonate,Arachidonate 12 Lipoxygenase Inhibitors,Arachidonate 15 Lipoxygenase Inhibitors,Arachidonate 5 Lipoxygenase Inhibitors,Inhibitor, 5-Lipoxygenase,Inhibitor, Lipoxygenase,Inhibitors, 12-Lipoxygenase,Inhibitors, 15-Lipoxygenase,Inhibitors, 5-Lipoxygenase,Inhibitors, Arachidonate 12-Lipoxygenase,Inhibitors, Arachidonate 15-Lipoxygenase,Inhibitors, Arachidonate 5-Lipoxygenase

Related Publications

W P Jackson, and P J Islip, and G Kneen, and A Pugh, and P J Wates
November 1993, Journal of medicinal chemistry,
W P Jackson, and P J Islip, and G Kneen, and A Pugh, and P J Wates
January 1996, Journal of medicinal chemistry,
W P Jackson, and P J Islip, and G Kneen, and A Pugh, and P J Wates
August 1999, Bioorganic & medicinal chemistry letters,
W P Jackson, and P J Islip, and G Kneen, and A Pugh, and P J Wates
July 1992, Journal of medicinal chemistry,
W P Jackson, and P J Islip, and G Kneen, and A Pugh, and P J Wates
September 2003, Bioorganic & medicinal chemistry,
W P Jackson, and P J Islip, and G Kneen, and A Pugh, and P J Wates
July 1991, Journal of medicinal chemistry,
W P Jackson, and P J Islip, and G Kneen, and A Pugh, and P J Wates
August 2013, Bioorganic & medicinal chemistry letters,
W P Jackson, and P J Islip, and G Kneen, and A Pugh, and P J Wates
September 1991, Agents and actions,
W P Jackson, and P J Islip, and G Kneen, and A Pugh, and P J Wates
January 1990, British journal of pharmacology,
W P Jackson, and P J Islip, and G Kneen, and A Pugh, and P J Wates
September 1993, Journal of medicinal chemistry,
Copied contents to your clipboard!